icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections
Seattle, Washington
Feb 19-22 2023
Back grey_arrow_rt.gif
 
 
 
COVID at CROI 2023
 
 
  CROI Feb 20-23
 
• Paxlovid reduced hositalization by 98%
• Bivalent booster reduced breakthrough & hospitalization by 75%
• COVID reduced new HV diagnoses & affects ETE, Blacks missed more diagnoses.
• New unboosted protease inhibitor Ensitrelvir is effective.
• One dose Pegylated Lambda interferon reduced by 89% death & hospitalization in unvaccinated.
• Inhaled Interferon for COVID did not establish efficacy.
• Metformin reduced CIVID viral load.
 

0327231

webcast: https://www.croiwebcasts.org/console/player/51741?mediaType=slideVideo&
 
For patients who received nirmatrelvir/ritonavir versus no therapy we observed a 99% relative reduction in risk.
 
In predictive models, older age was the most influential predictor of being hospitalized with COVID-19, while vaccination and outpatient therapy were the most influential factors predicting non-hospitalization.
 
[heart conditions, chronic kidney disease, Hispanic ethnicity, Delta variant all are associated with greater hospitalization risk.]

 

Booster

webcast: https://www.croiwebcasts.org/console/player/51875?mediaType=slideVideo&

0327232

0327233

0327234

webcast: https://www.croiwebcasts.org/console/player/51711?mediaType=slideVideo&

0327235

webcast: https://www.croiwebcasts.org/console/player/51731?mediaType=slideVideo&

0327236

webcast: https://www.croiwebcasts.org/console/player/51732?mediaType=slideVideo&

0327237

webcast: https://www.croiwebcasts.org/console/player/51735?mediaType=slideVideo&

0327238

webcast: https://www.croiwebcasts.org/console/player/51739?mediaType=slideVideo&
 
Metformin Reduced Long COVID Incidence by 43% - (03/07/23)

0327239